BC Extra | Sep 26, 2019
Preclinical News

Sept. 26 Preclinical Quick Takes: $30M for new lung disease lab; plus AI-derived compounds from Auransa, Atomwise, and diabetes candidates

Bayer, Brigham and Mass General open lung disease-focused lab  Bayer AG (Xetra:BAYN) will invest more than $30 million over five years to fund research into new treatments for chronic lung diseases, such as chronic obstructive...
BC Innovations | Sep 20, 2018
Distillery Therapeutics

Neurology; ophthalmic disease

INDICATION: Parkinson’s disease (PD); neurology; blindness Fruit fly studies suggest inhibiting ITPR, VDAC1, MCU, MIRO1 and/or MIRO2 could help treat PD, other neurodegenerative diseases and blindness. In a Drosophila model of PD, knockdown of ITPR...
BC Innovations | Oct 19, 2017
Translation in Brief

Go/No-Go decider

A Wistar Institute team has shown syntaphilin (SNPH) , known as a mitochondrial regulator in neurons, acts in cancer cells to mediate the decision of whether to proliferate or metastasize. While modulating the protein is a...
BC Innovations | Sep 18, 2014
Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Ras homolog family member T1 (Rhot1; Miro1)-deficient mouse models of motor neuron disease Miro1-deficient mice could be useful as models of motor neuron diseases. Miro1...
Items per page:
1 - 4 of 4